SG10201804151QA - Anti-egfr antibodies and uses thereof - Google Patents
Anti-egfr antibodies and uses thereofInfo
- Publication number
- SG10201804151QA SG10201804151QA SG10201804151QA SG10201804151QA SG10201804151QA SG 10201804151Q A SG10201804151Q A SG 10201804151QA SG 10201804151Q A SG10201804151Q A SG 10201804151QA SG 10201804151Q A SG10201804151Q A SG 10201804151QA SG 10201804151Q A SG10201804151Q A SG 10201804151QA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- egfr
- bind
- certain embodiments
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
ANTI-EGFR ANTIBODIES AND USES THEREOF The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the 5 present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders. 10 [No Figure]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261663984P | 2012-06-25 | 2012-06-25 | |
US201361821000P | 2013-05-08 | 2013-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201804151QA true SG10201804151QA (en) | 2018-07-30 |
Family
ID=48782632
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407163XA SG11201407163XA (en) | 2012-06-25 | 2013-06-25 | Anti-egfr antibodies and uses thereof |
SG10201804151QA SG10201804151QA (en) | 2012-06-25 | 2013-06-25 | Anti-egfr antibodies and uses thereof |
SG10201610590UA SG10201610590UA (en) | 2012-06-25 | 2013-06-25 | Anti-egfr antibodies and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407163XA SG11201407163XA (en) | 2012-06-25 | 2013-06-25 | Anti-egfr antibodies and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201610590UA SG10201610590UA (en) | 2012-06-25 | 2013-06-25 | Anti-egfr antibodies and uses thereof |
Country Status (24)
Country | Link |
---|---|
US (3) | US9132192B2 (en) |
EP (1) | EP2864357B1 (en) |
JP (1) | JP6486268B2 (en) |
KR (1) | KR20150023387A (en) |
CN (1) | CN104411722B (en) |
AR (1) | AR091545A1 (en) |
AU (2) | AU2013280610B2 (en) |
BR (1) | BR112014029099A2 (en) |
CA (1) | CA2876697C (en) |
CL (1) | CL2014003465A1 (en) |
CO (1) | CO7160093A2 (en) |
EA (1) | EA030421B1 (en) |
ES (1) | ES2816645T3 (en) |
HK (1) | HK1206040A1 (en) |
IL (1) | IL235392B (en) |
MX (1) | MX356329B (en) |
MY (2) | MY164604A (en) |
NZ (1) | NZ701633A (en) |
PH (1) | PH12014502437B1 (en) |
SG (3) | SG11201407163XA (en) |
TW (2) | TW201843172A (en) |
UY (1) | UY34876A (en) |
WO (1) | WO2014004427A2 (en) |
ZA (1) | ZA201407927B (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014007382A2 (en) | 2011-09-30 | 2017-04-04 | Regeneron Pharma | anti-erbb3 antibodies and their uses |
US9273143B2 (en) * | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
US9840560B2 (en) * | 2013-03-15 | 2017-12-12 | Alper Biotech Llc | Monoclonal antibodies to EGFR, and uses therefor |
CA2941030A1 (en) | 2014-02-28 | 2015-09-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
MX2016014926A (en) | 2014-05-16 | 2017-05-09 | Ablynx Nv | Improved immunoglobulin variable domains. |
BR122018009619B1 (en) * | 2014-05-16 | 2024-01-02 | Ablynx N.V | IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS |
TW202340452A (en) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | Taurine supplemented cell culture medium and methods of use |
CN105017424B (en) * | 2015-08-31 | 2021-02-09 | 北京泱深生物信息技术有限公司 | EGFR antibody variable region and application thereof |
HUE055222T2 (en) | 2015-10-23 | 2021-11-29 | Merus Nv | Binding molecules that inhibit cancer growth |
AU2016366521A1 (en) | 2015-12-11 | 2018-06-21 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to EGFR and/or ErbB3 blockade |
EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
MX2019011660A (en) | 2017-03-31 | 2019-11-18 | Merus Nv | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene. |
BR112020000127A2 (en) | 2017-07-06 | 2020-07-07 | Regeneron Pharmaceuticals, Inc. | method for selecting a soy hydrolyzate, and, glycoprotein |
CN111094351A (en) * | 2017-08-09 | 2020-05-01 | 美勒斯公司 | Antibodies binding to EGFR and cMET |
CN109912716B (en) * | 2017-12-13 | 2022-08-23 | 凯惠科技发展(上海)有限公司 | EGFR antibody and preparation method and application thereof |
AU2018392334A1 (en) | 2017-12-22 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
AU2019215363A1 (en) | 2018-01-31 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
TW202311746A (en) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | System and method for characterizing protein dimerization |
SG11202006310PA (en) | 2018-02-28 | 2020-07-29 | Regeneron Pharma | Systems and methods for identifying viral contaminants |
EP3765498A1 (en) * | 2018-03-14 | 2021-01-20 | F. Hoffmann-La Roche AG | Method for affinity maturation of antibodies |
CA3089655A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
TW202016125A (en) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | Systems and methods for quantifying and modifying protein viscosity |
CN108680746A (en) * | 2018-06-05 | 2018-10-19 | 中国科学院合肥物质科学研究院 | It is a kind of control lung carcinoma cell vigor molecular target and its application |
EP3774841A1 (en) | 2018-08-27 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
BR112020026348A2 (en) | 2018-08-30 | 2021-03-30 | Regeneron Pharmaceuticals, Inc. | METHOD FOR ASSESSING STEQUIOMETRY AND SIZE DISTRIBUTION OF PROTEIN COMPLEXES, FOR SELECTING A MAIN PROTEIN MEDICINE AND FOR CHARACTERIZING PROTEIN COMPLEXES, AND PHARMACEUTICAL COMPOSITION |
US11674968B2 (en) | 2019-01-16 | 2023-06-13 | Regeneran Pharmaceuticals, Inc. | Methods for identifying free thiols in proteins |
CA3134335A1 (en) | 2019-03-22 | 2020-10-01 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
JP2022532503A (en) | 2019-05-13 | 2022-07-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Improved competitive ligand binding assay |
WO2021013207A1 (en) * | 2019-07-24 | 2021-01-28 | 神州细胞工程有限公司 | Multivariable dosing method for use in treating high-egfr expression cancer |
CA3216345A1 (en) | 2019-09-24 | 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
IL293112A (en) | 2019-11-25 | 2022-07-01 | Regeneron Pharma | Sustained release formulations using non-aqueous emulsions |
JP7342279B2 (en) | 2020-01-21 | 2023-09-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Deglycosylation method for electrophoresis of glycosylated proteins |
BR112022017048A2 (en) | 2020-02-26 | 2022-11-16 | Vir Biotechnology Inc | ANTIBODIES AGAINST SARS-COV-2 AND METHODS FOR USING THEM |
CN116209772A (en) | 2020-08-31 | 2023-06-02 | 瑞泽恩制药公司 | Asparagine feed strategy for improving cell culture performance and reducing asparagine sequence variants |
IL303027A (en) | 2020-11-25 | 2023-07-01 | Regeneron Pharma | Sustained release formulations using non-aqueous membrane emulsification |
WO2022133135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
TW202233827A (en) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | Methods of improving protein titer in cell culture |
BR112023017442A2 (en) | 2021-03-03 | 2023-09-26 | Regeneron Pharma | Methods for identifying regions in a protein and for modifying the viscosity of a protein drug, and, protein drug |
KR20230162932A (en) | 2021-03-26 | 2023-11-29 | 리제너론 파아마슈티컬스, 인크. | Methods and systems for mixed protocol development |
US20230027739A1 (en) | 2021-05-10 | 2023-01-26 | Entrada Therapeutics, Inc. | Antigen-binding and antigen degradation constructs |
EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
TW202323817A (en) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Systems and methods of ph modeling and control |
CA3230985A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Ph meter calibration and correction |
CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
CN116333119B (en) * | 2021-12-16 | 2024-02-23 | 徕特康(苏州)生物制药有限公司 | anti-EGF receptor antibody, preparation method and application thereof |
TW202346856A (en) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | Methods and systems for analyzing polypeptide variants |
US20240027432A1 (en) | 2022-07-13 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Mild acid immunoassays for detection of analytes |
WO2024076926A1 (en) | 2022-10-03 | 2024-04-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies |
CN117430707B (en) * | 2023-10-25 | 2024-04-19 | 重庆天科雅生物科技有限公司 | Preparation method of CIK cells and application of CIK cells in treatment of cancers |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
PT699237E (en) | 1994-03-17 | 2003-07-31 | Merck Patent Gmbh | ANTI-EGFR CHAIN FVS AND ANTI-EGFR ANTIBODIES |
US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
AU2002257132A1 (en) * | 2001-04-06 | 2002-10-21 | The Trustees Of The University Of Pennsylvania | Erbb interface peptidomimetics and methods of use thereof |
MXPA03011365A (en) | 2001-06-13 | 2005-03-07 | Genmab As | Human monoclonal antibodies to epidermal growth factor receptor (egfr). |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
AU2002326531A1 (en) * | 2001-08-03 | 2003-02-17 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
PT2263691E (en) * | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2c4 (rhumab 2c4) |
US8323987B2 (en) * | 2004-02-17 | 2012-12-04 | The University Of North Carolina At Chapel Hill | Modulation of epidermal growth factor heterodimer activity |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
JP2009511032A (en) * | 2005-10-11 | 2009-03-19 | アブリンクス エン.ヴェー. | Nanobodies and polypeptides for EGFR and IGF-IR |
JP2009515878A (en) * | 2005-11-12 | 2009-04-16 | イーライ リリー アンド カンパニー | Anti-EGFR antibody |
US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
ES2398076T3 (en) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies against the human IL-6 receptor |
RU2448979C2 (en) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Human antibodies to delta-like human ligand-4 |
HUE025507T2 (en) * | 2008-03-18 | 2016-02-29 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
TWI496582B (en) * | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | Bispecific egfr/igfir binding molecules |
AR075896A1 (en) * | 2009-03-20 | 2011-05-04 | Genentech Inc | ANTI-HER ANTIBODIES (EPIDERMAL GROWTH FACTOR) |
KR20110126748A (en) * | 2009-04-07 | 2011-11-23 | 로슈 글리카트 아게 | Bispecific anti-erbb-1/anti-c-met antibodies |
JO3182B1 (en) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | High Affinity Human Antibodies to Human Angiopoietin-2 |
WO2011156617A2 (en) * | 2010-06-09 | 2011-12-15 | Aveo Pharmaceuticals, Inc. | Anti-egfr antibodies |
-
2013
- 2013-06-20 TW TW107129255A patent/TW201843172A/en unknown
- 2013-06-20 TW TW102121841A patent/TWI641619B/en not_active IP Right Cessation
- 2013-06-25 EA EA201590085A patent/EA030421B1/en not_active IP Right Cessation
- 2013-06-25 MY MYPI2014003097A patent/MY164604A/en unknown
- 2013-06-25 CN CN201380033859.6A patent/CN104411722B/en not_active Expired - Fee Related
- 2013-06-25 ES ES13735519T patent/ES2816645T3/en active Active
- 2013-06-25 NZ NZ701633A patent/NZ701633A/en not_active IP Right Cessation
- 2013-06-25 UY UY34876A patent/UY34876A/en unknown
- 2013-06-25 MY MYPI2017704291A patent/MY181086A/en unknown
- 2013-06-25 WO PCT/US2013/047476 patent/WO2014004427A2/en active Application Filing
- 2013-06-25 AR ARP130102231 patent/AR091545A1/en unknown
- 2013-06-25 SG SG11201407163XA patent/SG11201407163XA/en unknown
- 2013-06-25 MX MX2014014361A patent/MX356329B/en active IP Right Grant
- 2013-06-25 CA CA2876697A patent/CA2876697C/en active Active
- 2013-06-25 BR BR112014029099A patent/BR112014029099A2/en not_active Application Discontinuation
- 2013-06-25 SG SG10201804151QA patent/SG10201804151QA/en unknown
- 2013-06-25 SG SG10201610590UA patent/SG10201610590UA/en unknown
- 2013-06-25 KR KR20147035064A patent/KR20150023387A/en not_active Application Discontinuation
- 2013-06-25 AU AU2013280610A patent/AU2013280610B2/en active Active
- 2013-06-25 JP JP2015518639A patent/JP6486268B2/en active Active
- 2013-06-25 US US13/925,923 patent/US9132192B2/en active Active
- 2013-06-25 EP EP13735519.4A patent/EP2864357B1/en active Active
-
2014
- 2014-10-29 IL IL235392A patent/IL235392B/en active IP Right Grant
- 2014-10-30 ZA ZA2014/07927A patent/ZA201407927B/en unknown
- 2014-10-30 PH PH12014502437A patent/PH12014502437B1/en unknown
- 2014-12-19 CL CL2014003465A patent/CL2014003465A1/en unknown
- 2014-12-24 CO CO14283133A patent/CO7160093A2/en unknown
-
2015
- 2015-07-13 HK HK15106655.6A patent/HK1206040A1/en unknown
- 2015-08-06 US US14/820,324 patent/US9789184B2/en active Active
-
2017
- 2017-09-11 US US15/700,665 patent/US20180036405A1/en not_active Abandoned
-
2018
- 2018-07-05 AU AU2018204895A patent/AU2018204895A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201804151QA (en) | Anti-egfr antibodies and uses thereof | |
MX357391B (en) | Anti-erbb3 antibodies and uses thereof. | |
MX2018001532A (en) | Anti-angptl8 antibodies and uses thereof. | |
PH12015501493B1 (en) | Anti-pdgfr-beta antibodies and uses thereof | |
MX350861B (en) | Antibodies against epidermal growth factor receptor (egfr) and uses thereof. | |
MY193249A (en) | Anti-human cd19 antibodies with high affinity | |
NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
WO2012058592A3 (en) | Non-antagonistic egfr-binding molecules and immunoconjugates thereof | |
MX370721B (en) | Novel compounds and compositions for targeting cancer stem cells. | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
MY179577A (en) | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof | |
MX2020012426A (en) | Anti-cd38 antibodies. | |
WO2012058588A3 (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
MX2022001086A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof. | |
WO2010022736A3 (en) | Recombinant anti-epidermal growth factor receptor antibody compositions | |
JO3291B1 (en) | Antibodies against csf-1r | |
WO2017079570A3 (en) | Splise-switching oligonucleotides and methods of use | |
MX2016001236A (en) | Afucosylated anti-fgfr2iiib antibodies. | |
JO3246B1 (en) | High affinity human antibodies to human protease-activated receptor-2 | |
MY184241A (en) | Human antibodies to gfr?3 and methods of use thereof | |
MX2017006167A (en) | Glycan-interacting compounds and methods of use. | |
WO2015054600A3 (en) | Glycan-interacting compounds and methods of use | |
MX2012013875A (en) | Peripheral blood sparc antibodies and uses thereof. | |
MX2014001766A (en) | Neuregulin antibodies and uses thereof. |